Volver a la clasificación

Penumbra, Inc. (PEN)

NEUTRAL
HealthcareMedical DevicesUnited States

Fundamental

67

Precio

$324.74

Capitalización Bursátil

$12.79B

Parte 1 · Cuánto vale la empresa

Resumen

Penumbra designs and manufactures devices that remove blood clots from inside the body without open surgery, threading a catheter through a blood vessel to pull the clot out or suck it away. Its products treat conditions such as ischemic stroke, pulmonary embolism and acute limb ischemia. A second, related line of products helps physicians access blood vessels and block off unwanted ones, such as before a tumor is removed. It sells to hospitals and clinics in over 100 countries.

Cómo genera ingresos

Penumbra sells physical devices — catheters, aspiration systems and related disposables — to hospitals, which use them one procedure at a time. Because each stroke, clot or vascular case consumes a new device, revenue grows with the number of procedures performed rather than through subscriptions, and it depends on hospitals adopting Penumbra's technology over rival devices, on regulatory clearance for new products, and on reimbursement from insurers and public health systems that pay for the procedure.

Ingresos por segmento

Thrombectomy67.5%

Devices that remove blood clots to treat pulmonary embolism, deep vein thrombosis, acute limb ischemia, ischemic stroke and coronary disease.

Embolization and Access32.5%

Devices that help physicians access blood vessels and selectively block off unwanted ones, used in a range of vascular procedures.

Ventaja competitiva

Patentes y licencias · Estrecha

Penumbra's devices are protected by patents on their specific mechanical and aspiration designs, and any new device must clear a lengthy regulatory approval process before it can be sold, which slows down copycats. That said, the field has several capable competitors building similar clot-removal technology, so the protection is real but not close to exclusive.

Qué impulsa la demanda

Defensivo

Penumbra's core products treat medical emergencies such as stroke, pulmonary embolism and limb-threatening blood clots, procedures that hospitals perform regardless of the economic climate because delaying them risks death or permanent disability. Demand is therefore driven mainly by disease incidence, physician adoption of minimally invasive techniques, and hospital budgets for equipment, not by discretionary consumer spending.

Riesgos clave

  • Lengthy and uncertain regulatory approval — The company operates under stringent domestic and foreign medical device regulations, and delays or failures in obtaining approval for new or modified products can push back launches and revenue.
  • Product liability litigation — As a maker of devices used in life-critical procedures, the company faces product liability claims and lawsuits seeking compensatory and punitive damages over alleged device failures or injuries.
  • Restrictions on off-label promotion — Regulators actively enforce rules against promoting a device for uses it was not approved for, and a violation can bring substantial monetary penalties or criminal prosecution.
  • Mandatory adverse event reporting — Medical device reporting rules require the company to notify regulators whenever it learns a device may have caused or contributed to a death or serious injury, which can trigger investigations or recalls.

Los argumentos a favor

Buyers argue that thrombectomy is still replacing older, less effective treatments for stroke and clot-related emergencies, that Penumbra's revenue keeps growing faster than the market, and that its second embolization and access line adds a further avenue for growth beyond its original thrombectomy business.

Los argumentos en contra

Sellers fear that well-funded competitors are developing similar clot-removal technology, that a single unfavorable regulatory finding or product-liability case could damage both revenue and reputation quickly, and that a business built on emergency procedures leaves little room to grow through pricing.

Datos por segmento del ejercicio fiscal 2025Fuentes: Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$1.50B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$161M

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

$175M

Patrimonio Neto Total

$1.43B

Pasivo Total

$399M

Ratio de Liquidez

5.75

Cobertura de Intereses

144.33

Deuda/EBITDA

1.03

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Sobrevalorado

Valor Justo

$238.51

Precio Actual

$324.74

Margen de Seguridad

-36.2%

Rango de Valor Justo

$155.03 - $321.99

Métodos de Estimación

Analyst Target:$361.83
DCF:$106.51
PE-based:$280.42
Graham Growth:$66.10
EPV:$44.76
Consenso de Analistas:Mantener (6B / 14H / 0S)
Última Sorpresa de Resultados:-26.59%

Métricas de Valoración

Ratio P/E

79.55

ROE

12.4%

Ratio P/B

8.33

P/FCF

59.06

Margen Bruto

67.8%

ROIC

8.5%

Radar de Rentabilidad

Value Creation (Economic Moat)

ROIC

8.5%

WACC

8.2%

ROIC − WACC

+0.3 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

Criterios de Análisis Fundamental

Superado (18)

  • EPS shows upward trend
  • EPS CAGR 33.58%
  • Price CAGR 17.69%
  • ROIC 8.5%
  • Gross Margin 67.8%
  • Debt/Equity ratio
  • Operating Margin 12.4%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 11.1%
  • Revenue Growth 5Y 20.2%
  • Earnings Quality (OCF/NI) 1.73
  • Share Dilution 1.0%
  • Piotroski F-Score 8/9

Fallido (8)

  • P/FCF 59.06
  • P/B Ratio 8.33
  • CapEx intensity
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 30% Buy
  • Earnings Surprise avg -10.5%
  • Net Margin Trend 10.7% vs 11.5%

No disponible (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

8/9

Solidez financiera fuerte

score
criteria

Calidad de los Beneficios

1.73

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

1.0%

El número de acciones es estable

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Adam Elsesser J.D.Co-Founder, Chairman & CEO63
Ms. Shruthi NarayanPresident40
Dr. Arani Bose M.D.Co-Founder & Director63
Ms. Maggie S. YuenChief Financial Officer53
Mr. Lambert ShiuChief Accounting Officer45
Ms. Johanna Roberts J.D.Executive VP, General Counsel & Secretary53
Mr. Ben SorciExecutive Vice President of Operations-
Mr. Pankaj TiwariExecutive VP & Chief Information Officer-

Riesgo de Auditoría

7

Riesgo del Consejo

5

Riesgo de Compensación

7

Riesgo de Derechos del Accionista

4

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for PEN, sourced from Markets Gazette.

  • 2/25/2026NEUTRAL
    Penumbra Q4 Earnings Assessment

    The financial community is keenly awaiting the assessment of Penumbra Inc.'s fourth-quarter earnings. While specific details from this analysis have not yet been released, investor attention remains high, given the critical importance of such reports in gauging the medical device company's financial health and future prospects. Q4 performance is particularly crucial for Penumbra, operating in a competitive medical technology market where innovation and clinical outcomes drive growth. Analysts will be closely scrutinizing key metrics such as revenue figures, profit margins, and forward-looking guidance for the upcoming year, seeking indications of the company's ability to sustain its growth trajectory and navigate industry challenges. The full disclosure of these results will provide clear direction for the stock.

via Markets Gazette